An experimental treatment appears to delay Alzheimer’s symptoms in some people genetically destined to get the disease in ...

Investigators said that the OLE study showed Roche’s gantenerumab dropped the risk of developing symptoms by 50%.

For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from ...

A study of Roche's anti-amyloid drug gantenerumab has suggested that early treatment to remove amyloid plaques from the brain ...

While the clinical dementia findings did not reach statistical significance, they were the first to provide a hint that early ...

An experimental treatment appears to delay Alzheimer’s symptoms in some people genetically destined to get the disease in their 40s or 50s, according to new findings from ongoing research now caught ...

An appointment with Wendell Helveston, M.D., a neurologist in Hattiesburg, MS, led to a series of diagnostic tests, such as ...

So, what’s really going on? In early 2023, the U.S. Food and Drug Administration (FDA) granted accelerated approval to a new Alzheimer’s drug called Leqembi. (Biogen, a biotechnology company ...

It's hard to trust the disease statistics when cognitive tests often are not completed, write Robert Brownell and Dr. Yogesh ...

Recent research suggests lecanemab may be less effective in females, raising important questions for future Alzheimer’s drug ...

Meanwhile, two similar drugs — lecanemab, or Leqembi, and donanemab, or Kisunla — did meet the US Food and Drug Administration’s bar and were approved to treat people with Alzheimer’s who ...